Stephen Harnicar

483 total citations
18 papers, 293 citations indexed

About

Stephen Harnicar is a scholar working on Hematology, Transplantation and Molecular Biology. According to data from OpenAlex, Stephen Harnicar has authored 18 papers receiving a total of 293 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Hematology, 5 papers in Transplantation and 3 papers in Molecular Biology. Recurrent topics in Stephen Harnicar's work include Renal Transplantation Outcomes and Treatments (5 papers), Hematopoietic Stem Cell Transplantation (5 papers) and Chronic Lymphocytic Leukemia Research (3 papers). Stephen Harnicar is often cited by papers focused on Renal Transplantation Outcomes and Treatments (5 papers), Hematopoietic Stem Cell Transplantation (5 papers) and Chronic Lymphocytic Leukemia Research (3 papers). Stephen Harnicar collaborates with scholars based in United States. Stephen Harnicar's co-authors include Alexander Drilon, Dazhi Liu, Michael Offin, Bob T. Li, Jonathan Wills, Nelly G. Adel, Gerald A. Soff, Simon Mantha, Yimei Miao and Joseph G. Jurcic and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and The American Journal of Cardiology.

In The Last Decade

Stephen Harnicar

17 papers receiving 287 citations

Peers

Stephen Harnicar

CCM

ONCOL

PRM

Ariane Vieira Scarlatelli Macedo Brazil

Christelle Orlando Belgium

Omri Cohen Israel

Ghislaine Dufaître France

Mirela Tuzovic United States

Magda Verga Italy

Zsuzsanna Wolf Germany

Rashid Kazmi United Kingdom

S. Friard France

Anja A. van Houten United Kingdom

Ariane Vieira Scarlatelli Macedo Brazil

Stephen Harnicar

67 ×0.7

194 ×2.0

CCM

118 ×1.4

ONCOL

59 ×0.9

49 ×0.8

PRM

Citations per year, relative to Stephen Harnicar Stephen Harnicar (= 1×) peers Ariane Vieira Scarlatelli Macedo

Countries citing papers authored by Stephen Harnicar

Since Specialization

Citations

This map shows the geographic impact of Stephen Harnicar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephen Harnicar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephen Harnicar more than expected).

Fields of papers citing papers by Stephen Harnicar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stephen Harnicar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephen Harnicar. The network helps show where Stephen Harnicar may publish in the future.

Co-authorship network of co-authors of Stephen Harnicar

This figure shows the co-authorship network connecting the top 25 collaborators of Stephen Harnicar. A scholar is included among the top collaborators of Stephen Harnicar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stephen Harnicar. Stephen Harnicar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Hough, Shannon, et al.. (2023). Oncology pharmacy practice in the United States: Results of a comprehensive, nationwide survey. Journal of Oncology Pharmacy Practice. 30(2). 332–341. 6 indexed citations

Liu, Dazhi, Marcus D. Goncalves, James J. Harding, et al.. (2022). Characterization, management, and risk factors of hyperglycemia during PI3K or AKT inhibitor treatment. Cancer Medicine. 11(8). 1796–1804. 22 indexed citations

D, Liu, et al.. (2018). Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors. SHILAP Revista de lepidopterología. 4 indexed citations

Shah, Gunjan L., Andrew Lin, Ryan Schofield, et al.. (2018). Feasibility and Toxicity of Pharmacokinetic (PK)-Directed Dosing of Evomela® (propylene glycol free melphalan, PGF-MEL) for Multiple Myeloma (MM) and AL Amyloidosis (AL) Patients Undergoing Autologous Hematopoietic Stem Cell Transplant (AHCT). Biology of Blood and Marrow Transplantation. 24(3). S129–S130. 2 indexed citations

Liu, Dazhi, Michael Offin, Stephen Harnicar, Bob T. Li, & Alexander Drilon. (2018). Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors. Therapeutics and Clinical Risk Management. Volume 14. 1247–1252. 83 indexed citations

Shah, Gunjan L., Andrew Lin, Ryan Schofield, et al.. (2017). Feasibility, Tolerability, and Patient-Reported Outcomes with Pharmacokinetic (PK)-Directed Dosing of Evomela® (propylene glycol free melphalan) for Multiple Myeloma and AL Amyloidosis Patients Undergoing Autologous Hematopoietic Stem Cell Transplant (AHCT). Blood. 130. 2023–2023. 2 indexed citations

Shah, Gunjan L., Heather Landau, Ryan Schofield, et al.. (2017). Pharmacokinetics and Toxicities after Evomela® (propylene glycol free melphalan) with Autologous Hematopoietic Stem Cell Transplant (AHCT) for Multiple Myeloma and AL Amyloidosis. Blood. 130. 3296–3296. 2 indexed citations

Yu, Anthony F., Dipti Gupta, Yimei Miao, et al.. (2017). Rivaroxaban for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation and Active Cancer. The American Journal of Cardiology. 120(2). 213–217. 34 indexed citations

Mantha, Simon, Yimei Miao, Debra Sarasohn, et al.. (2016). Safe and effective use of rivaroxaban for treatment of cancer-associated venous thromboembolic disease: a prospective cohort study. Journal of Thrombosis and Thrombolysis. 43(2). 166–171. 73 indexed citations

10.

Yu, Anthony F., Dipti Gupta, Yimei Miao, et al.. (2016). Rivaroxaban for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation and Active Cancer. Blood. 128(22). 2621–2621. 6 indexed citations

11.

Harnicar, Stephen, Doris M. Ponce, Patrick Hilden, et al.. (2015). Intensified Mycophenolate Mofetil Dosing and Higher Mycophenolic Acid Trough Levels Reduce Severe Acute Graft-versus-Host Disease after Double-Unit Cord Blood Transplantation. Biology of Blood and Marrow Transplantation. 21(5). 920–925. 24 indexed citations

12.

Ponce, Doris M., Stephen Harnicar, Patrick Hilden, et al.. (2014). Intensified Mycophenolate Mofetil (MMF) Dosing Is Safe from the Standpoint of Engraftment and Reduces Severe Acute Graft-Versus-Host Disease (aGVHD) after Double-Unit Cord Blood Transplantation (DCBT): An Analysis of 173 Patients. Biology of Blood and Marrow Transplantation. 20(2). S279–S280. 1 indexed citations

13.

Harnicar, Stephen, Doris M. Ponce, Junting Zheng, et al.. (2014). Higher Mycophenolic Acid (MPA) Trough Levels Result in Lower Day 100 Severe Acute Graft-Versus-Host Disease (aGVHD) without Increased Toxicity in Double-Unit Cord Blood Transplantation (CBT) Recipients. Biology of Blood and Marrow Transplantation. 20(2). S52–S53. 1 indexed citations

14.

Harnicar, Stephen, et al.. (2014). Spotlight on nilotinib in the treatment of chronic myelogenous leukemia. 61–61. 1 indexed citations

15.

Harnicar, Stephen, Doris M. Ponce, Junting Zheng, et al.. (2013). Higher Mycophenolic Acid (MPA) Trough Levels Result In Lower Day 100 Severe Acute GVHD Without Increased Toxicity In Double-Unit Cord Blood Transplantation (CBT) Recipients. Blood. 122(21). 3297–3297. 1 indexed citations

16.

Ponce, Doris M., Stephen Harnicar, Sean M. Devlin, et al.. (2013). Intensified Mycophenolate Mofetil (MMF) Dosing Every 8 Hours Is Safe From The Standpoint Of Engraftment and May Ameliorate Severe Acute Graft-Versus-Host Disease (GVHD) After Double-Unit Cord Blood Transplantation (CBT). Blood. 122(21). 4600–4600. 1 indexed citations

17.

Harnicar, Stephen. (2011). Pharmacotherapy for Chronic Myelogenous Leukemia: A Case-Based Approach. Journal of the National Comprehensive Cancer Network. 9(Suppl_3). S–25. 1 indexed citations

18.

Harnicar, Stephen, Nelly G. Adel, & Joseph G. Jurcic. (2009). Modification of vincristine dosing during concomitant azole therapy in adult acute lymphoblastic leukemia patients. Journal of Oncology Pharmacy Practice. 15(3). 175–182. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact